Test Module 2

The World Health Organization (WHO) has launched target product profiles to drive the rapid development of novel tuberculosis (TB) preventive treatment today. The target product profiles characterise the most important product attributes to be considered for developing the best suited TB prevention treatments in future.

One quarter of the global population is estimated to be infected with TB and are at greater risk of developing TB disease, especially those with weakened immunity. Treatment of T

Roles: Everyone: All Users

Regions: Canada , France , Italy , United Kingdom

Topics: Global Health

The fourth meeting of the Emergency Committee convened by the WHO Director-General under the International Health Regulations (IHR) (2005) regarding the coronavirus disease (COVID-19) took place on Friday, 31 July 2020 from 12:00 to 17:45 Geneva time (CEST). 

Proceedings of the meeting

Members and advisors of the Emergency Committee were convened by vid

Roles: Everyone: All Users

Regions: United Kingdom

Topics: Coronavirus (COVID-19), Global Health, Science, Technology, and Innovation

• Seventy-five countries submit expressions of interest to COVAX Facility, joining up to 90 further countries which could be supported by the COVAX Advance Market Commitment (AMC)
• The COVAX Facility, and the AMC within it, is designed to guarantee rapid, fair and equitable access to COVID-19 vaccines for every country in the world, rich and poor, to make rapid progress towards slowing the pandemic 
  
• Interest from governments represen

  Roles: Everyone: All Users

  Regions: Argentina, Canada , Norway , United Kingdom

  Topics: Coronavirus (COVID-19), Global Health, Refugee and Humanitarian Assistance, Science, Technology, and Innovation

• Statement on the 5th meeting of the International Health Regulations (2005) Emergency Committee for Ebola virus disease in the Democratic Republic of the Congo on 14 April 2020

  Roles: Everyone: All Users

  Topics: Coronavirus (COVID-19), Global Health